Vertex Reports Positive Week 36 Interim Results in Phase 3 RAINIER Trial of Povetacicept for IgA Nephropathy
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Vertex Pharmaceuticals Incorporated…
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy
First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for…
Regeneron Pharmaceuticals-Licensed Olatorepatide Shows Positive Phase 3 Results for Obesity in Chinese Patients
Obesity Drug Olatorepatide, Licensed by Regeneron Pharmaceuticals, Shows Positive Phase 3 Outcomes in Chinese Patients Regeneron Pharmaceuticals, Inc. today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its…
Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results…
Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis
Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults…
Enhertu Receives U.S. Priority Review for Post-Neoadjuvant Treatment of HER2-Positive Early Breast Cancer
Enhertu receives U.S. Priority Review as a post-neoadjuvant therapy for patients with early-stage HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted…
AbbVie Reports Positive Topline Results from Phase 1 Multiple Ascending Dose Study of Long-Acting Amylin Analog ABBV-295 in Adults
AbbVie reports positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog evaluated in adults. AbbVie (NYSE: ABBV) today announced positive topline results1 from…
Novo Nordisk Expands U.S. Access to FDA-Approved Semaglutide Medicines via Hims & Hers Health Partnership
Novo Nordisk broadens U.S. patient access to FDA-approved semaglutide treatments through Hims & Hers following a strategic shift in its U.S. GLP-1 business approach. Novo Nordisk today announced it has…
TECVAYLI® Plus DARZALEX FASPRO® Wins FDA Approval for Relapsed/Refractory Multiple Myeloma
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed or Refractory Multiple Myeloma Halozyme Therapeutics has announced that Johnson & Johnson has received approval from the U.S. Food…
Celltrion Plans to Cancel 9.11 Million Treasury Shares to Boost Shareholder Value Amid Market Uncertainty
Celltrion Plans Cancellation of 9.11 Million Treasury Shares to Strengthen Shareholder Value Amid Market Volatility Celltrion has announced a significant corporate governance and capital management initiative aimed at strengthening shareholder…
European Commission Approves Zynyz for First-Line Treatment of Advanced Anal Cancer, Says Incyte
European Commission Approves Zynyz® (retifanlimab) as a First-Line Treatment for Patients with Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Incyte has announced that the European Commission has granted…
NEJM Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Reduces Lupus Disease Activity
NEJM Publishes Phase III ALLEGORY Results Showing Gazyva Reduces Disease Activity in Common Lupus Genentech, a member of the Roche Group, has announced that detailed results from the Phase III…